Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: Conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery

Stuart A. Grossman, Carlos G. Romo, Michelle A. Rudek, Jeffrey Supko, Joy Fisher, L. Burt Nabors, Patrick Y. Wen, David M. Peereboom, Benjamin M. Ellingson, William Elmquist, Fred G. Barker, David Kamson, Jann N. Sarkaria, William Timmer, Ranjit S. Bindra, Xiaobu Ye

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: Conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery'. Together they form a unique fingerprint.

Medicine & Life Sciences